{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:23:37Z","timestamp":1790774617475,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Temporal lobe epilepsy (TLE) is associated with significant comorbidities, including cognitive decline and psychiatric disorders. Myokines, such as irisin and meteorin\u2010like (METRNL) hormone, are secreted during physical activity and possess neuroprotective and anti\u2010inflammatory properties. This study aimed to evaluate serum irisin and METRNL concentrations in people with TLE (drug\u2010resistant and drug\u2010responsive) compared to healthy controls and to analyze their correlation with depression, anxiety, cognitive function, and physical activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This cross\u2010sectional study included adult participants divided into three groups: drug\u2010resistant TLE, drug\u2010responsive TLE, and healthy controls. Serum irisin and METRNL levels were quantified using ELISA. Neuropsychological status was assessed using the Beck Depression Inventory (BDI), Spielberger State\u2013Trait Anxiety Inventory (STAI), and Mini\u2010Mental State Examination (MMSE). Physical activity was evaluated using the International Physical Activity Questionnaire (IPAQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum METRNL levels were significantly lower in both the drug\u2010resistant and drug\u2010responsive TLE groups compared to the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.001). Multivariable regression analysis confirmed that epilepsy status was independently associated with lower METRNL levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.039). Conversely, serum irisin levels did not differ significantly among the groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.124). Participants with TLE exhibited significantly lower physical activity and MMSE scores compared to controls. Additionally, the drug\u2010resistant TLE group showed significantly higher depression and state anxiety scores. A positive correlation was observed between physical activity levels and serum METRNL concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum METRNL levels are significantly reduced in people with TLE regardless of drug resistance, whereas irisin levels remain unchanged. The reduction in METRNL may reflect underlying neuroinflammatory or metabolic dysfunctions associated with epilepsy. Given the association between physical activity and METRNL, lifestyle interventions may offer therapeutic potential. METRNL warrants further investigation as a candidate biomarker for TLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epd2.70212","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:57:50Z","timestamp":1773014270000},"page":"1058-1068","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of serum irisin and meteorin\u2010like (\n                    <scp>METRNL<\/scp>\n                    ) levels in people with drug\u2010resistant and drug\u2010responsive temporal lobe epilepsy"],"prefix":"10.1002","volume":"28","author":[{"given":"Esranur","family":"Kaya","sequence":"first","affiliation":[{"name":"Department of Neuroscience Erciyes University  Kayseri Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-9768","authenticated-orcid":false,"given":"\u015eeyma","family":"Benli","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ministry of Health Af\u015fin State Hospital  Kahramanmara\u015f Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem Barlak","family":"Keti","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry Faculty of Medicine, Erciyes University  Kayseri Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Ko\u011f","sequence":"additional","affiliation":[{"name":"Department of Physiology School of Medicine, Ko\u00e7 University  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravza","family":"Tosunbayraktar","sequence":"additional","affiliation":[{"name":"Department of Neuroscience Erciyes University  Kayseri Turkey"},{"name":"Gevher Nesibe Genome and Stem Cell Institute, Erciyes University  Kayseri Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00fcsun Ferda","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Neuroscience Erciyes University  Kayseri Turkey"},{"name":"Department of Neurology Faculty of Medicine, Erciyes University  Kayseri Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12550"},{"key":"e_1_2_14_3_1","unstructured":"World Health Organization.Epilepsy.2019Available from:https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/epilepsy"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074\u20107742(08)00020\u20102"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2007.01222.x"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2010.0298"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2006.00702.x"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883\u2010014\u20100194\u2010z"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14596"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255\u2010021\u201000438\u2010z"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10777"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.738533"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12264\u2010022\u201000914\u2010w"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2016.9"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2014.04.012"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00301"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010019\u20100174\u2010x"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.12.003"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15301"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2018.1503992"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806\u20109282.67.02.20200521"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70286"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epd2.70212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:48:33Z","timestamp":1787395713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epd2.70212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/epd2.70212"],"URL":"https:\/\/doi.org\/10.1002\/epd2.70212","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}